News

InfraReDx to Play Active Role in 18th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium in Washington

Presentations will Cover Detection of Vulnerable Coronary Plaque and Company’s NIR-based Plaque-characterization Technology

October 17, 2006 — BURLINGTON, Massachusetts

InfraReDx, Inc., a company that is investigating the use of near-infrared (NIR) spectroscopy for the detection of lipid-rich coronary artery plaque, will present its progress at the Cardiovascular Research Foundation’s 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., October 22-27, 2006. In its initial appearance at TCT, the company will also display its novel catheter, as well as promising experimental data, at a booth (number 1266) in the exhibit hall.

Dr. James Muller, InfraReDx’s founder, CEO, president, and chief medical officer, will be participating in three sessions:

• Tuesday, October 24: He will be delivering a talk – “Approaches to the Vulnerable Plaque and the Vulnerable Patient: Today and Tomorrow” – at a session devoted to “Acute Coronary Syndromes and Myocardial Infarction.”
• Thursday, October 26: He will be participating in the main event of a vulnerable plaque symposium, addressing the question: Does focal plaque-directed therapy to stabilize the coronary tree make sense? Dr. Muller’s response will be yes: vulnerable plaque is a focal disease, the cure of which warrants the risks of local therapy
• Thursday, October 26: He will be moderating a discussion of regional plaque passivation strategies.

Also on the TCT schedule are relevant presentations by the following independent investigators: Dr. Sergio Waxman, M.D., associate professor of medicine at Tufts University School of Medicine, and director of interventional cardiovascular research at the Lahey Clinic; as well as Pavan K. Cheruvu, M.Sc., a student in the Health Sciences and Technology program of the Massachusetts Institute of Technology, and Craig Gardner, Ph.D., director of algorithm development at InfraReDx.

Dr.Waxman will deliver a talk on the progress of his study of InfraReDx’s NIR spectroscopy system in patients (Thursday, October 26). He will also participate in a panel presentation on evaluating the physical properties of vulnerable plaque (Thursday, October 26).

As part of the vulnerable plaque symposium on Thursday, Mr. Cheruvu will be presenting the results of a study – “Density and Distribution of Thin Cap Fibroatheroma and Ruptured Plaque in Human Coronary Arteries—A Pathologic Study.” Dr. Gardner will also be presenting the results of another study as an electronic abstract: “Identification of Thin-Capped Fibroatheroma through Blood with Probe-based Near-Infrared Spectroscopy in Human Coronary Autopsy Specimens.”;

InfraReDx, Inc., founded in 1998 and headquartered in Burlington, Massachusetts, is a privately-funded company developing a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify vulnerable plaques in the coronary arteries. For more information, visit www.infraredx.com.

TCT is organized by the Cardiovascular Research Foundation, which is dedicated to research and education in the broad subspecialty of interventional cardiology and endovascular medicine. The TCT meeting is the primary annual meeting for the world-wide interventional cardiology community. For more information, visit www.crf.org.

Contact:

Mike Napack
InfraReDx, Inc.
mnapack@infraredx.com